Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Alpine Immune Sciences has entered into a collaboration agreement with Merck to evaluate the efficacy and safety of Alpine’s checkpoint in combination with Merk’s anti-PD-1 therapy in cancer.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The new funding will be used to advance the company’s potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor furmonertinib, a lung cancer treatment that has been licensed from Allist Pharmaceuticals.
Christina Smolke said the financing will enable the company to use its synthetic biology platform to support essential medications that rely on plant-based materials.
The company said it would halt activities and focus its resources and time on liver and obesity research following “disappointing” results of its intranasal COVID-19 vaccine.
The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.
Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.
Life sciences news sometimes flies under the radar. So here’s a look at a few stories you may have missed.
Every week there are numerous scientific studies published. This week there was an unusual number of research stories revolving around Alzheimer’s disease. Here’s a look at some of the more interesting ones.
The cash infusion will support the growth of its manufacturing capabilities in the US and the UK and the demands for gene therapies, antibodies, and vaccines such as COVID-19.
Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.
The COVID-19 pandemic has led to faster R&D, faster approvals, faster science than ever before. It’s even leading to faster company development.